Leukocyte Differential Compared on Flow Cytometry Hematology Analyzer
By LabMedica International staff writers Posted on 10 Sep 2012 |

Image: The DxH 800 Cellular Analysis System (Photo courtesy of Beckman Coulter).
A recently introduced automated hematology analyzer that provides a 16-part white blood cell count (WBC) differential has been compared with other automated machines and the manual method.
The newer flow cytometry-hematology analyzer is not only able to differentiate the five main white cell populations but also capable of distinguishing 11 other cells including immature blast cells and various T-lymphocytes.
Scientists at Dong-A University (Busan, South Korea) selected 101 blood samples in routine complete blood counts (CBC) for analysis regardless of previous diagnosis. The samples came from 54 men and 47 women, whose age range was 1-84 years, with a mean age of 43 years. The Hematoflow, the newest automatic hematology analyzer, includes a DxH 800 Coulter Cellular Analysis System and FC 500 Flow Cytometer (Beckman Coulter; Miami, FL, USA). The DxH800 uses multiple angles of light scatter, and the FC500 provides a 16-part WBC differential, giving precise information on WBC subsets.
The FC500 contains a premixed Cytodiff reagent and analysis software. The Cytodiff panel included six directly conjugated monoclonal antibodies in a five-color single reagent. The differential WBC count performance of the FC500, was compared with the Beckman Coulter DxH800, the Sysmex XE-2100 (TOA Medical Electronics Co.; Kobe, Japan), and the reference manual method. The methodological comparison of the WBC differential parameters of neutrophils, lymphocytes, monocytes and eosinophils showed good correlations among four different analyses. More than 1% of blast cells were counted in 30 of 101 samples.
For B-cell acute lymphatic leukaemia (ALL), blast B count of Hematoflow shows good correlation with reference method results. The analyzer easily distinguished B-cell lineage leukemic blasts from T-cell leukemic blasts and myeloblasts. For T-cell ALL, Hematoflow did not identify blast T, and shows complete agreement with manual counting. For acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), blast non-B-non-T counts of Hematoflow shows 100% concordance and good correlation with reference method results.
The scientists concluded that for the technical staff, the installation of Hematoflow would have many consequences. There would be a reduction in technical staff time at the microscope while simultaneously increasing the efficiency of the workflow, the elimination of medical technologists facing a difficult diagnosis alone. This rapid and quantitative technique may be helpful in the differential diagnosis of acute leukemias prior to additional investigation. The study was published in the October 2012 edition of the International Journal of Laboratory Hematology.
Related Links:
Dong-A University
Beckman Coulter
TOA Medical Electronics Co.
The newer flow cytometry-hematology analyzer is not only able to differentiate the five main white cell populations but also capable of distinguishing 11 other cells including immature blast cells and various T-lymphocytes.
Scientists at Dong-A University (Busan, South Korea) selected 101 blood samples in routine complete blood counts (CBC) for analysis regardless of previous diagnosis. The samples came from 54 men and 47 women, whose age range was 1-84 years, with a mean age of 43 years. The Hematoflow, the newest automatic hematology analyzer, includes a DxH 800 Coulter Cellular Analysis System and FC 500 Flow Cytometer (Beckman Coulter; Miami, FL, USA). The DxH800 uses multiple angles of light scatter, and the FC500 provides a 16-part WBC differential, giving precise information on WBC subsets.
The FC500 contains a premixed Cytodiff reagent and analysis software. The Cytodiff panel included six directly conjugated monoclonal antibodies in a five-color single reagent. The differential WBC count performance of the FC500, was compared with the Beckman Coulter DxH800, the Sysmex XE-2100 (TOA Medical Electronics Co.; Kobe, Japan), and the reference manual method. The methodological comparison of the WBC differential parameters of neutrophils, lymphocytes, monocytes and eosinophils showed good correlations among four different analyses. More than 1% of blast cells were counted in 30 of 101 samples.
For B-cell acute lymphatic leukaemia (ALL), blast B count of Hematoflow shows good correlation with reference method results. The analyzer easily distinguished B-cell lineage leukemic blasts from T-cell leukemic blasts and myeloblasts. For T-cell ALL, Hematoflow did not identify blast T, and shows complete agreement with manual counting. For acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), blast non-B-non-T counts of Hematoflow shows 100% concordance and good correlation with reference method results.
The scientists concluded that for the technical staff, the installation of Hematoflow would have many consequences. There would be a reduction in technical staff time at the microscope while simultaneously increasing the efficiency of the workflow, the elimination of medical technologists facing a difficult diagnosis alone. This rapid and quantitative technique may be helpful in the differential diagnosis of acute leukemias prior to additional investigation. The study was published in the October 2012 edition of the International Journal of Laboratory Hematology.
Related Links:
Dong-A University
Beckman Coulter
TOA Medical Electronics Co.
Latest Hematology News
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
RNA Blood Test Detects Cancers and Resistance to Treatment
A newly developed blood test offers the ability to detect cancer, understand how cancer resists treatments, and assess tissue damage from non-cancerous conditions. This innovative test, created by researchers... Read more
IL-6 Outperforms Traditional Tests for Early Sepsis Detection
Sepsis, a severe and life-threatening condition caused by the immune system’s exaggerated response to infection, remains a major cause of death globally, responsible for approximately 11 million fatalities... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read more
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more